 Patient Recruitment Underway NEW YORK, Jan. 25, 2023 PRNewswire Hoth Therapeutics, Inc. NASDAQ: HOTH, a patient-focused biopharmaceutical company, today announced that it has selected 3 of its clinical sites for its Phase 2a clinical trial for the treatment for rash and skin disorders associated with epidermal growth factor receptor EGFR inhibitor therapy. EGFR inhibitors are ...... 